Uncategorized
This week in Drug Discovery (13 – 17 April)
News round-up for 13 – 17 April by Bruno Quinney, Content Team at DDW.
This week, breakthroughs have emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical trial set up in the UK.
The top stories:
Novel therapy could slow tumour growth
A novel cancer therapy targeting tumour acidity could boost immune response and slow cancer growth, studies show.
B7-H4-targeted ADC shows 62% response rate in ovarian cancer
The global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (Mo-Rez) has shown confirmed objective response rates (cORR) of 62% in platinum-resistant ovarian cancer (PROC) and 67% in recurrent or advanced endometrial cancer (EC).
Immunopeptide could delay inflammatory arthritis, study says
Scientists investigating the naturally occurring immunopeptide PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) have shown reductions in arthritic joint swelling to a degree comparable to the current standard of care, reducing inflammatory changes that cause joint damage.
Speech overlooked as clinical marker, biotech says
SynaptixBio, which became the only company to commercialise a treatment for the rare disease H-ABC, is set to launch a study into speech as a non-invasive, digital clinical marker in neurodegenerative disease research.
Read more…
Regulatory reforms accelerate UK clinical trial set up
NHS patients are accessing groundbreaking treatments faster as the UK government fulfils its promise for a 150-day clinical trial target.
Read more…
The post This week in Drug Discovery (13 – 17 April) appeared first on Drug Discovery World (DDW).